New drug combo for myeloid blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug (ICP-248) combined with standard treatment azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). It aims to find out if the combo is safe and effective for those who haven't been helped by other treatments or cannot have strong chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of AML (except a specific type called APL) or MDS.
- For AML: You either have not responded to or relapsed after previous treatment, or you are newly diagnosed and age 60 or older (or age 18-59 with health issues making strong chemo unsafe).
- For MDS: You score higher than 3 on a standard risk scale and more than 5% of your bone marrow cells are blasts (immature cells).
- Your doctor expects you to live at least 12 more weeks.
- Your kidneys and liver work well enough (creatinine clearance at least 30 mL/min and normal liver tests).
- You have not had azacitidine or a similar drug (BCL-2 inhibitor) without improvement or with side effects.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a study testing a new combination treatment—mitoxantrone liposome, cytarabine, G-CSF + venetoclax—against the usual combination of azacitidine and venetoclax for people with certain high-risk blood cancers like secondary AML or MDS-IB2. The goal is to see if the new combo works better.
This trial tests a new drug combination (iadademstat plus azacitidine and venetoclax) for people with newly diagnosed AML who cannot have or do not want standard intensive chemotherapy. The goal is to see if adding iadademstat makes the treatment work better.
This trial tests a new drug called APG1252 combined with azacitidine (AZA) for people with high-risk AML or certain related blood cancers. The goal is to see if the combination works better than standard treatments.
This trial tests a new drug, MAX-40279, combined with two standard treatments (venetoclax and azacitidine) for people with newly diagnosed acute myeloid leukemia who are not healthy enough for intensive chemotherapy. The goal is to see if adding this drug improves outcomes.
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
This study tests a new drug (BMS-986497) alone or combined with two other medicines (azacitidine and venetoclax) for people with AML or MDS that has not responded to or returned after prior treatments. The goal is to see if this combination can help control the disease.
Hear when a new Acute Myelogenous Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.